オプションチェーンは、Amarin Corpの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Amarin Corpの市場センチメントを評価します。.

Amarin Corp (NASDAQ:AMRN) 株価情報, オプションチェーン

Amarin Corp

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.

Amarin Corporation plc - American Depositary Shares

Amarin Corp PLC

<h3>Gainers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares increased by 65.8% to $0.42 during Friday's pre-market session. The company's market cap stands at $16.7 million. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) shares increased by 16.81% to $2.64. The market value of their outstanding shares is at $154.6 million. The company's, Q1 earnings came out today. </li>
<li>American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) shares rose 16.15% to $7.19. The market value of their outstanding shares is at $113.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) stock moved upwards by 15.94% to $1.6. The company's market cap stands at $22.9 million. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares rose 12.93% to $1.22. The market value of their outstanding shares is at $41.5 million. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) shares moved upwards by 12.76% to $2.12. The market value of their outstanding shares is at $42.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) stock fell 18.8% to $0.82 during Friday's pre-market session. The company's market cap stands at $51.3 million. </li>
<li>Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) stock decreased by 18.65% to $4.45. The company's market cap stands at $1.0 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares decreased by 17.45% to $0.22. The company's market cap stands at $10.0 million. </li>
<li>Tvardi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVRD#NASDAQ">TVRD</a>) shares fell 17.1% to $21.1. The company's market cap stands at $197.4 million. </li>
<li>Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) stock fell 15.76% to $9.25. The market value of their outstanding shares is at $3.8 billion. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares declined by 11.97% to $2.06. The market value of their outstanding shares is at $103.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AIRS

AMRN

AMWL

ARDX

ATPC

CAMP

CTSO

HCTI

MODV

PLRZ

RMTI

TVRD

12 Health Care Stocks Moving In Friday's Pre-Market Session

-- Nasdaq Compliance Follows ADS Ratio Change to Secure Company's Public Listing --
-- Amarin Remains Focused on Maximizing the Global Value of VASCEPA/VAZKEPA –
DUBLIN and BRIDGEWATER, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) today announced it has regained compliance with the Nasdaq Stock Market ("Nasdaq") continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications.
On April 29, 2025, the Company received confirmation from the Listing Qualifications Department of Nasdaq that as of April 28, 2025 the Company's common stock had maintained an average closing share price of at least $1.00 over the last 10 consecutive business days ending on that date. Accordingly, the Company's shares are no longer considered to be below the minimum bid price requirement of Rule 5550(a)(2) and, as a result, the Company has regained compliance with the Nasdaq continued listing standards. Nasdaq now considers this matter closed.
Amarin is now in full compliance with all Nasdaq listing requirements and will continue to be listed and traded on Nasdaq.

News

Amarin Regains Compliance With Nasdaq Minimum Bid Price Requirement; Nasdaq Compliance Follows ADS Ratio Change to Secure Company's Public Listing

As of April 25, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Lexicon Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>)</h3>
<ul>
<li>On March 28, Lexicon Pharmaceuticals entered into an exclusive license agreement with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtains an exclusive, worldwide license to develop, manufacture, and commercialize LX9851 in all indications. The company's stock jumped around 95% over the past month and has a 52-week high of $2.45.</li>
<li>RSI Value: 73.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>LXRX Price Action: Shares of Lexicon Pharmaceuticals gained 4.7% to close at $0.70 on Thursday.</li>
<li>Edge Stock Ratings: 5.71 Momentum score with Value at 55.06. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/lxrx"><img loading="lazy" decoding="async" width="472" height="182" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25045347/image-168.png" alt="" class="wp-image-888292" style="width:303px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25045347/image-168.png 472w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25045347/image-168-300x116.png 300w" sizes="(max-width: 472px) 100vw, 472px" /></a></figure>
<h3 class="wp-block-heading">Amarin Corporation PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>)</h3>
<ul>
<li>On March 12, Amarin announced its intent to effect a 1-for-20 ADS ratio change. The company also reported fourth-quarter financial results. &#8220;Since taking on the role of CEO of Amarin last year, I have worked with our leadership team and the Board of Directors to identify opportunities to leverage our unique assets, skills and resources to drive value,&#8221; said Aaron Berg, President &amp; CEO, Amarin. &#8220;In 2024, while still progressing with the early launch in markets outside the U.S. and despite a dynamic generic market in the U.S., we generated more than $200 million in revenue and ended the year with nearly $300 million in cash and no debt &#8212; all measures exemplifying the strength and resilience of our franchise and the impact of our disciplined approach to capital deployment.&#8221; The company's stock gained around 24% over the past five days and<a href="https://www.benzinga.com/quote/AMRN"> has a 52-week high</a> of $20.60.</li>
<li>RSI Value: 73.5</li>
<li>AMRN Price Action: Shares of Amarin rose 7.9% to close at $11.18 on Thursday.</li>
</ul>
BZ Edge Rankings: Find out where other stocks stand—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">explore the full comparison now</a>. 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44977071/wall-streets-most-accurate-analysts-weigh-in-on-3-materials-stocks-with-over-7-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Materials Stocks With Over 7% Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

LXRX

Top 2 Health Care Stocks That May Crash This Month

Goldman Sachs analyst Paul Choi maintains Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) with a Sell and lowers the price target from $20 to $7.

Price Target

Analyst Ratings

Goldman Sachs Maintains Sell on Amarin Corp, Lowers Price Target to $7

U.S. stocks were higher, with the Nasdaq Composite gaining over 200 points on Monday.
Shares of Hyatt Hotels Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) fell sharply during <a href="https://www.benzinga.com/quote/H/analyst-ratings">Monday's session</a>.
Goldman Sachs analyst Lizzie Dove downgraded Hyatt Hotels from Neutral to Sell and lowered the price target from $150 to $110.
Hyatt Hotels shares fell 2.2% to $110.13 on Monday.
Here are some other big stocks recording losses in today's session.
<ul>
<li>Alumis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares dipped 9.9% to $5.84.</li>
<li>Nutex Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) tumbled 9.9% to $119.00.</li>
<li>Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) shares fell 9.3% to $8.44.</li>
<li>Clear Channel Outdoor Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCO#NYSE">CCO</a>) shares declined 8.2% to $0.9453.</li>
<li>MarineMax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HZO#NYSE">HZO</a>) fell 5.9% to $17.75. Truist Securities analyst Michael Swartz maintained MarineMax with a Buy and lowered the price target from $38 to $26.</li>
<li>Wheels Up Experience Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UP#NYSE">UP</a>) dipped 5.7% to $0.8010.</li>
<li>ECARX Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECX#NASDAQ">ECX</a>) fell 5.6% to $0.8969. ECARX Holdings will report its financial results for the first quarter, before the opening bell on Wednesday, April 30.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) declined 5.5% to $3.2200.</li>
<li>SBC Medical Group Holdings Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBC#NASDAQ">SBC</a>) fell 4.8% to $4.00. SBC Medical Group completed its purchase of 5 BTC as of April 14.</li>
<li>THOR Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) fell 2.5% to $67.25. Truist Securities analyst Michael Swartz maintained Thor Industries with a Hold and lowered the price target from $90 to $72.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/04/44759831/top-3-industrials-stocks-that-may-explode-in-april">Top 3 Industrials Stocks That May Explode In April</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

ALMS

NUTX

SHLS

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

U.S. stocks were lower, with the Dow Jones index dipping over 250 points on Friday.
Shares of Fastenal Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) rose sharply during Thursday's session following better-than-<a href="https://www.benzinga.com/news/earnings/25/04/44761872/fastenal-beats-revenue-estimates-in-q1-but-margins-narrow-as-costs-rise">expected first-quarter sales.</a>
Fastenal on Friday reported first-quarter 2025 revenue of $1.959 billion, a 3.4% year-over-year increase and slightly above the $1.95 billion consensus estimate. Adjusting for one less selling day and the absence of Good Friday in March, net daily sales grew 5.0%.
Fastenal shares jumped 3.3% to $78.31 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>CeriBell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBLL#NASDAQ">CBLL</a>) shares jumped 30.3% to $14.52.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) gained 28% to $5.77.</li>
<li>Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) rose 19.3% to $30.72. The stock may be moving up after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.</li>
<li>Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) gained 16.2% to $28.26.</li>
<li>Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) rose 15.2% to $2.8300.</li>
<li>Schrödinger, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>) gained 13.6% to $21.84.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) jumped 13.55% to $32.07.</li>
<li>Certara, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) rose 12.6% to $11.84. Baird analyst Joe Vruwink maintained Certara with a Neutral and raised the price target from $9 to $13.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>) gained 12% to $8.18.</li>
<li>BeiGene, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>) gained 10.6% to $230.00.</li>
<li>Newsmax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMAX#NYSE">NMAX</a>) gained 10.6% to $28.11.</li>
<li>AngloGold Ashanti plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>) rose 8.5% to $42.15.</li>
<li>Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) jumped 7.6% to $9.72.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44759875/mckesson-to-rally-more-than-11-here-are-10-top-analyst-forecasts-for-friday">McKesson To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Friday</a> </li>
</ul>
Photo via Shutterstock

ABSI

CBLL

CERT

FAST

NMAX

RXRX

SDGR

ZLAB

Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) today highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicosapentaenoic&nbsp;acid (EPA) on lipoprotein(a) [Lp(a)]-enriched plasma and the effects of a glucagon-like peptide-1 (GLP-1) receptor agonist in combination with EPA on the expression of proteins in endothelial cells.

Biotech

General

Amarin Highlights Recent Data Presented At ACC.25 Evaluating Mechanistic Effects Of Eicosapentaenoic Acid In Lp(a)-Enriched Plasma And In Combination With GLP-1 Agonist

WIIM

Amarin Corporation shares are trading lower after the company announced its intent to effect a 1-for-20 ADS ratio change. The company reported Q4 financial results.

The company continues to&nbsp;tightly manage its operating expenses and its cash position. The company reaffirms its belief that current cash and investments and other assets are adequate to support continuing operations for the foreseeable future.

Amarin Says Continuing To Explore All Strategies To Accelerate Growth In Europe Region

Stock Split

Amarin To Effect An ADS Ratio Change From 1 ADS Representing 1 Ordinary Share To 1 ADS Representing 20 Ordinary Shares (1-For-20)

Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.05) by 60 percent. The company reported quarterly sales of $62.31 million which beat the analyst consensus estimate of $35.92 million by 73.48 percent. This is a 16.61 percent decrease over sales of $74.71 million the same period last year.

Earnings

Earnings Beats

Amarin Corp Q4 2024 Adj EPS $(0.02) Beats $(0.05) Estimate, Sales $62.31M Beat $35.92M Estimate

<h3>Companies Reporting Before The Bell</h3>
• EHang Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) is projected to report quarterly loss at $0.07 per share on revenue of $23.36 million. 
• Hello Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>) is projected to report quarterly earnings at $0.21 per share on revenue of $365.05 million. 
• Chicago Atlantic Real (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) is estimated to report quarterly earnings at $0.56 per share on revenue of $14.19 million. 
• Waterdrop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) is expected to report earnings for its fourth quarter. 
• Upland Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPLD#NASDAQ">UPLD</a>) is projected to report quarterly earnings at $0.20 per share on revenue of $67.84 million. 
• VNET Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $284.88 million. 
• Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) is likely to report quarterly earnings at $0.06 per share on revenue of $107.94 million. 
• Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $200.59 million. 
• Arcos Dorados Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCO#NYSE">ARCO</a>) is likely to report quarterly earnings at $0.21 per share on revenue of $1.15 billion. 
• Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $194.15 million. 
• OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $30.36 million. 
• Navigator Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVGS#NYSE">NVGS</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $120.87 million. 
• ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) is projected to report quarterly earnings at $0.78 per share on revenue of $2.09 billion. 
• Smith Douglas Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDHC#NYSE">SDHC</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $265.85 million. 
• Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) is expected to report quarterly loss at $0.03 per share on revenue of $32.37 million. 
• ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) is expected to report quarterly earnings at $3.49 per share on revenue of $2.02 billion. 
• Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) is projected to report quarterly earnings at $0.13 per share on revenue of $161.60 million. 
• National Energy Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NESR#NASDAQ">NESR</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $339.84 million. 
• iRobot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) is expected to report quarterly loss at $1.73 per share on revenue of $171.00 million. 
• Ondas Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONDS#NASDAQ">ONDS</a>) is expected to report quarterly loss at $0.09 per share on revenue of $5.75 million. 
• BingEx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLX#NASDAQ">FLX</a>) is expected to report earnings for its fourth quarter. 
• InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) is likely to report quarterly loss at $0.19 per share on revenue of $1.82 million. 
• United Homes Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>) is estimated to report earnings for its fourth quarter. 
• Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $24.15 million. 
• MagnaChip Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MX#NYSE">MX</a>) is expected to report quarterly loss at $0.19 per share on revenue of $61.57 million. 
<h3>Companies Reporting After The Bell</h3>
• Vasta Platform (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTA#NASDAQ">VSTA</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $110.28 million. 
• KLX Energy Services Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLXE#NASDAQ">KLXE</a>) is expected to report quarterly loss at $0.80 per share on revenue of $168.90 million. 
• Algoma Steel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTL#NASDAQ">ASTL</a>) is expected to report earnings for its third quarter. 
• Comtech Telecom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) is projected to report quarterly loss at $0.25 per share on revenue of $129.53 million. 
• Aris Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARIS#NYSE">ARIS</a>) is estimated to report earnings for its fourth quarter. 
• Legacy Housing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGH#NASDAQ">LEGH</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $44.59 million. 
• Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) is expected to report quarterly loss at $0.19 per share on revenue of $36.66 million. 
• Montauk Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTK#NASDAQ">MNTK</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $56.32 million. 
• Ellington Credit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EARN#NYSE">EARN</a>) is expected to report quarterly earnings at $0.30 per share on revenue of $9.65 million. 
• FreightCar America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIL#NASDAQ">RAIL</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $152.02 million. 
• PHX Minerals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHX#NYSE">PHX</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $8.93 million. 
• Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) is expected to report quarterly earnings at $1.82 per share on revenue of $1.64 billion. 
• SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) is estimated to report quarterly loss at $0.21 per share on revenue of $222.33 million. 
• ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) is likely to report earnings for its fourth quarter. 
• UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $425.34 million. 
• SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) is estimated to report quarterly loss at $1.50 per share on revenue of $710 thousand. 
• RCM Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCMT#NASDAQ">RCMT</a>) is expected to report quarterly earnings at $0.83 per share on revenue of $79.00 million. 
• Beauty Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKIN#NASDAQ">SKIN</a>) is projected to report quarterly loss at $0.09 per share on revenue of $77.45 million. 
• Fathom Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTHM#NASDAQ">FTHM</a>) is projected to report quarterly loss at $0.17 per share on revenue of $84.70 million. 
• Cardlytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDLX#NASDAQ">CDLX</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $63.63 million. 
• Biote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTMD#NASDAQ">BTMD</a>) is likely to report quarterly earnings at $0.17 per share on revenue of $51.20 million. 
• Limoneira (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>) is projected to report quarterly loss at $0.17 per share on revenue of $40.70 million. 
• Calavo Growers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGW#NASDAQ">CVGW</a>) is expected to report quarterly earnings at $0.29 per share on revenue of $161.55 million. 
• KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) is likely to report quarterly loss at $0.02 per share on revenue of $8.89 million. 
• American Eagle Outfitters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) is likely to report quarterly earnings at $0.51 per share on revenue of $1.60 billion. 
• Berry Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRY#NASDAQ">BRY</a>) is expected to report quarterly earnings at $0.15 per share on revenue of $173.00 million. 
• Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) is projected to report quarterly loss at $0.19 per share on revenue of $108.91 million. 
• Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) is projected to report quarterly earnings at $4.97 per share on revenue of $5.66 billion. 
• electroCore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECOR#NASDAQ">ECOR</a>) is expected to report quarterly loss at $0.34 per share on revenue of $7.29 million. 
• AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $9.73 million. 
• BGSF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGSF#NYSE">BGSF</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $67.65 million. 
• CI&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CINT#NYSE">CINT</a>) is projected to report earnings for its fourth quarter. 
• Companhia Siderurgica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SID#NYSE">SID</a>) is projected to report quarterly loss at $0.09 per share on revenue of $1.94 billion. 
• Performant Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHLT#NASDAQ">PHLT</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $34.15 million. 
• Urgently (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULY#NASDAQ">ULY</a>) is expected to report earnings for its fourth quarter. 
• Assertio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASRT#NASDAQ">ASRT</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $28.67 million. 
• Quest Resource Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRHC#NASDAQ">QRHC</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $73.63 million. 
• CPS Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPSH#NASDAQ">CPSH</a>) is estimated to report earnings for its fourth quarter. 
• Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>) is expected to report earnings for its third quarter. 
• Zedge (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZDGE#AMEX">ZDGE</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $7.71 million. 
• NextNav (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NN#NASDAQ">NN</a>) is expected to report quarterly loss at $0.14 per share on revenue of $1.73 million. 
• Monogram Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRM#NASDAQ">MGRM</a>) is estimated to report earnings for its fourth quarter. 
• Fossil Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOSL#NASDAQ">FOSL</a>) is likely to report earnings for its fourth quarter. 
• Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $29.00 million. 
• Aris Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMN#AMEX">ARMN</a>) is likely to report earnings for its fourth quarter. 
• Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $116.82 million. 
• Tilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLYS#NYSE">TLYS</a>) is expected to report quarterly loss at $0.29 per share on revenue of $159.90 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADBE

AEYE

ANIK

ARCO

ARIS

ARMN

ASRT

ASTL

BGSF

BRLT

BTMD

CDLX

CINT

CMTL

CPSH

CVGW

EARN

ECOR

FOSL

FTHM

HBIO

IRBT

KEQU

KLXE

KRMD

LEGH

LMNR

LOGC

MGRM

MNTK

MOMO

NESR

NKTR

NSPR

NVGS

ONDS

OPRX

PATH

PHLT

QRHC

RAIL

RCMT

REFI

SDHC

SEAT

SKIN

SNES

TLYS

UPLD

VNET

VSTA

ZDGE

Earnings Scheduled For March 12, 2025

Amarin Published Data In Journal Of The American Heart Association Showing Post-Hoc Analysis Of REDUCE-IT Study Among Statin-Treated Patients With Elevated Triglycerides And High Cardiovascular Risk, VASCEPA/VAZKEPA

Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) today announced that Peter Fishman has been appointed as Chief Financial Officer for the Company, effective immediately. He will be responsible for leading Amarin's global finance organization and will report directly to the Company's Chief Executive Officer, Aaron Berg. Most recently, Mr. Fishman served as the Company's Global Controller and principal financial and accounting officer.

Management

Amarin Appoints Peter Fishman CFO, Effective Immediately

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Silence Therapeutics PLC &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>)</h3>
<ul>
<li>On Nov. 14, Silence Therapeutics reported a quarterly loss of 75 cents per share, versus a year-ago loss of 9 cents per share The company reported $1.49 million in sales. &#8220;The Silence team is focused on continued execution across the business,&#8221; said Craig Tooman, President and Chief Executive Officer at Silence. &#8220;We look forward to presenting additional data from our wholly owned clinical programs at upcoming medical meetings and progressing our pipeline to bring innovative gene silencing medicines to patients around the world.&#8221; The company's stock fell around 37% over the past five days and has a <a href="https://www.benzinga.com/quote/SLN">52-week low of $9.22</a>.</li>
<li>RSI Value: 12.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>SLN Price Action: Shares of Silence Therapeutics fell 13.2% to close at $11.02 on Monday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111924&amp;t=be2bearmibe3na1">latest SLN news.</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="823" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042649/image-187.png" alt="" class="wp-image-654486" style="width:787px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042649/image-187.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042649/image-187-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042649/image-187-768x693.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">Terns Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>)&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Nov. 12, Terns Pharma posted a third-quarter loss of 28 cents per share, compared to market estimates for a loss of 34 cents per share. &#8220;Our progress in the third quarter was highlighted by the compelling topline results from our Phase 1 study of TERN-601, which demonstrated class-leading potential as a differentiated, once-daily, oral GLP-1R agonist for the treatment of obesity and supports its rapid advancement into Phase 2 studies,&#8221; stated Amy Burroughs, chief executive officer of Terns. The company's stock fell around 22% over the past five days and <a href="https://www.benzinga.com/quote/TERN">has a 52-week low</a> of $3.59.</li>
<li>RSI Value: 26.34</li>
<li>TERN Price Action: Shares of Terns Pharmaceuticals fell 7.6% to close at $5.70 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111924&amp;t=be2bearmibe3na1">trend in TERN stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="920" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042754/image-188.png" alt="" class="wp-image-654492" style="width:667px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042754/image-188.png 920w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042754/image-188-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042754/image-188-768x695.png 768w" sizes="(max-width: 920px) 100vw, 920px" /></a></figure>
<h3 class="wp-block-heading">Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>)</h3>
<ul>
<li>On Oct. 30, Amarin posted a quarterly loss of 6 cents per share, compared to market estimates of a loss of 5 cents per share. Aaron Berg, Amarin&#8217;s President and CEO stated, &#8220;While we and our global partners continue to execute on our multipronged global strategy focused on getting VASCEPA/VAZKEPA into the hands of as many patients as possible, the senior leadership team and I, as well as the Board of Directors, remain committed to evaluating all opportunities to maximize the value and impact of this highly impactful product. To that end, we look forward to highlighting the global opportunity for VASCEPA/VAZKEPA and to hear directly from both prescribers and select partners from around the world on the impact of VASCEPA/VAZKEPA during our upcoming virtual Analyst and Investor Day on November 14.&#8221; The company's stock fell around 16% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/AMRN">low of $0.46</a>.</li>
<li>RSI Value: 25.86</li>
<li>AMRN Price Action: Shares of Amarin fell 7% to close at $0.46 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111924&amp;t=be2bearmibe3na1">breakout in AMRN shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="632" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042902/image-189.png" alt="" class="wp-image-654498" style="width:659px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042902/image-189.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042902/image-189-300x207.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042902/image-189-768x529.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42035732/jim-cramer-super-group-basic-materials-stock-is-very-hard-to-own-here">Jim Cramer: Super Group Finally &#8216;Broke Out,&#8217; This Basic Materials Stock Is &#8216;Very Hard To Own Here&#8217;</a></li>
</ul>

Long Ideas

TERN

Top 3 Health Care Stocks You'll Regret Missing In Q4

Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) today announced that investigators will present an additional subgroup analysis from the landmark REDUCE-IT outcomes trial in patients with and without coronary artery disease (CAD) history and mechanistic data on eicosapentaenoic acid (EPA) at the American Heart Association's Scientific Sessions, November 16-18, 2024 in Chicago, IL.
"The data to be presented at the AHA Scientific Sessions continues to affirm the clinical utility and value of VASCEPA&#xAE;/VAZKEPA&#xAE; (icosapent ethyl), not only in the overall REDUCE-IT trial population, but also across various subgroups analyzed to date," said Steve Ketchum, PhD, Chief Scientific Officer at Amarin. "Data presented at AHA will showcase new evidence from the REDUCE-IT CAD subanalysis, highlighting the benefits of VASCEPA/VAZKEPA in secondary prevention patients, with and without CAD history."
Dr. Ketchum further added, "Additional data to be featured at the AHA Scientific Sessions include research highlighting the mechanistic effects of EPA, particularly its antioxidant effects in endothelial cells and the ability of EPA to impact the oxidation of Lp(a) particles. High Lp(a) concentrations are associated with increased CV event risk, and people with high levels face a 2-4 times greater risk of having an early event. With about 20% of the global population affected, research is crucial for understanding and addressing elevated Lp(a)."

Amarin Corporation Announces That Investigators Will Present An Additional Subgroup Analysis From The REDUCE-IT Outcomes Trial In Patients With And Without Coronary Artery Disease History And Mechanistic Data On Eicosapentaenoic Acid At The American Heart Association's Scientific Sessions

Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.05) by 20 percent. The company reported quarterly sales of $42.300 million which missed the analyst consensus estimate of $44.510 million by 4.96 percent. This is a 35.96 percent decrease over sales of $66.056 million the same period last year.

Earnings Misses

Amarin Corp Q3 2024 GAAP EPS $(0.06) Misses $(0.05) Estimate, Sales $42.300M Miss $44.510M Estimate

Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) today announced new supported and/or funded subgroup data from the landmark REDUCE-IT&#xAE; cardiovascular outcomes trial with VASCEPA&#xAE;/VAZKEPA&#xAE; (icosapent ethyl), as well as abstracts showcasing the mechanistic activity of eicosapentaenoic&nbsp;acid (EPA) that will be presented at the European Society of Cardiology (ESC) Congress in London, United Kingdom, August 30 – September 2, 2024.
The accepted abstracts include a REDUCE-IT subgroup analysis to assess if baseline small dense low density lipoprotein cholesterol (sdLDL-C) modifies the effect of icosapent ethyl (IPE) on cardiovascular events. A second abstract examines the association of triglycerides with cardiovascular events in patients with initial or recurrent acute coronary syndrome (ACS). A third abstract estimates the number of ACS patients eligible for IPE in Spanish hospitals, and finally, a fourth abstract measures the effects of EPA on oxidation of Lp(a) under experimental conditions of high glucose.

Amarin Shares Latest Research Highlighting VASCEPA/VAZKEPA REDUCE-IT Subgroup Data And New Mechanistic Insights Into Eicosapentaenoic Acid To Be Presented At ESC Congress 2024

Health Care

Press Releases

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action

Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist

Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Comments

Amarin Corp

Amarin Corp (AMRN) オプション

Amarin Corp (NASDAQ:AMRN) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル